Serevent (salmeterol), is now approved for chronic obstructive pulmonary disease (COPD)

March 1998

    The long-acting beta-agonist, Serevent (salmeterol), is now approved for chronic obstructive pulmonary disease (COPD). It used to be approved just for asthma.

    Serevent will be used as an alternative to Atrovent (ipratropium)...some patients will use them together.

    One advantage is that Serevent is dosed BID...instead of TID to QID like Atrovent.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote